Stock TRML TOURMALINE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
16.96 USD +2.17% Intraday chart for Tourmaline Bio, Inc. +21.75% -35.22%
May. 16 Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial CI
May. 13 Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
GL
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
GL
Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
CI
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected
MT
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady
MT
Top Premarket Decliners
MT
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027
MT
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024
CI
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing
MT
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GL
Tourmaline Bio Prices $150 Million Common Stock Offering
MT
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRML Stock
  4. News Tourmaline Bio, Inc.